Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3727893 | 0.94 | ADORA1 (0.70) | ADORA1SLC6A3 | |
| SCHEMBL3728434 | 0.93 | ADORA1 (0.75) | ADORA1SLC6A3 | |
| SCHEMBL3739334 | 0.92 | ADORA1 (0.79) | ADORA1SLC6A3 | |
| SCHEMBL13227826 | 0.91 | ADORA1 (0.68) | ADORA1SLC6A3 | |
| SCHEMBL3730903 | 0.90 | ADORA1 (0.73) | ADORA1SLC6A3 | |
| SCHEMBL7904995 | 0.89 | ADORA1 (0.62) | ADORA1SLC6A3 | |
| SCHEMBL7893973 | 0.88 | ADORA1 (0.59) | ADORA1SLC6A3 | |
| SCHEMBL3730825 | 0.88 | ADORA1 (0.72) | ADORA1SLC6A3 | |
| SCHEMBL3727883 | 0.88 | ADORA1 (0.72) | ADORA1SLC6A3 | |
| SCHEMBL1932981 | 0.88 | ADORA1 (0.85) | ADORA1SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160311812-A1 | ADENOSINE A1 AGONISTS AS MEDICAMENTS FOR KIDNEY DISORDERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-10-27 | — | — | US | claimed |
| EP-2391620-B1 | ALKYLAMINE-SUBSTITUTED DICYANOPYRIDINE AND AMINO ACID ESTER PRODRUGS THEREOF | BAYER IP GMBH (DE) | 2014-05-07 | — | — | EP | claimed |
| US-8420825-B2 | Alkylamino-substituted dicyanopyridines and their amino acid ester prodrugs | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-04-16 | — | — | US | claimed |
| WO-2018219804-A1 | SELF-MICROEMULSIFYING DRUG DELIVERY SYSTEMS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-12-06 | — | — | WO | disclosed |
| WO-2018153897-A1 | SELECTIVE PARTIAL ADENOSINE A1 RECEPTOR AGONISTS IN COMBINATION WITH HCN CHANNEL BLOCKERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-08-30 | — | — | WO | disclosed |
| WO-2018153898-A1 | SELECTIVE PARTIAL ADENOSINE A1 RECEPTOR AGONISTS IN COMBINATION WITH MINERALOCORTICOID RECEPTOR ANTAGONISTS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-08-30 | — | — | WO | disclosed |
| WO-2018153900-A1 | SELECTIVE PARTIAL ADENOSINE A1 RECEPTOR AGONISTS IN COMBINATION WITH SGLT-2 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2018-08-30 | — | — | WO | disclosed |
| WO-2018153895-A1 | SELECTIVE PARTIAL ADENOSINE A1 RECEPTOR AGONISTS IN COMBINATION WITH A NEUTRAL ENDOPEPTIDASE INHIBITOR AND/OR AN ANGIOTENSIN II RECEPTOR ANTAGONIST | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-08-30 | — | — | WO | disclosed |
| EP-2743270-B1 | Alkylamino-substituted dicyanopyridines and their amino acid ester prodrugs | BAYER IP GMBH (DE) | 2016-12-21 | — | — | EP | disclosed |
| EP-2743270-B1 | Alkylamino-substituted dicyanopyridines and their amino acid ester prodrugs | BAYER IP GMBH (DE) | 2016-12-21 | — | — | EP | disclosed |
| US-20160311812-A1 | ADENOSINE A1 AGONISTS AS MEDICAMENTS FOR KIDNEY DISORDERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-10-27 | — | — | US | disclosed |
| US-20130267700-A1 | ALKYLAMINE-SUBSTITUTED DICYANOPYRIDINE AND AMINO ACID ESTER PRODRUGS THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-10-10 | — | — | US | disclosed |
| US-20130267700-A1 | ALKYLAMINE-SUBSTITUTED DICYANOPYRIDINE AND AMINO ACID ESTER PRODRUGS THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-10-10 | — | — | US | disclosed |
| US-8420825-B2 | Alkylamino-substituted dicyanopyridines and their amino acid ester prodrugs | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-04-16 | — | — | US | disclosed |
| US-8420825-B2 | Alkylamino-substituted dicyanopyridines and their amino acid ester prodrugs | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-04-16 | — | — | US | disclosed |
| EP-2391620-A1 | ALKYLAMINE-SUBSTITUTED DICYANOPYRIDINE AND AMINO ACID ESTER PRODRUGS THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2011-12-07 | — | — | EP | disclosed |
| WO-2010086101-A1 | ALKYLAMINE-SUBSTITUTED DICYANOPYRIDINE AND AMINO ACID ESTER PRODRUGS THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-08-05 | — | — | WO | disclosed |
| WO-2010086101-A1 | ALKYLAMINE-SUBSTITUTED DICYANOPYRIDINE AND AMINO ACID ESTER PRODRUGS THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-08-05 | — | — | WO | disclosed |
| US-20100197609-A1 | ALKYLAMINO-SUBSTITUTED DICYANOPYRIDINES AND THEIR AMINO ACID ESTER PRODRUGS | Bayer Schering Pharma (DE) | 2010-08-05 | — | — | US | disclosed |
| US-20100197609-A1 | ALKYLAMINO-SUBSTITUTED DICYANOPYRIDINES AND THEIR AMINO ACID ESTER PRODRUGS | Bayer Schering Pharma (DE) | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267700-A1 | ALKYLAMINE-SUBSTITUTED DICYANOPYRIDINE AND AMINO ACID ESTER PRODRUGS THEREOF | AADAT, DDC, DNPEP | ADORA1 402/4885SLC6A3 399/4885 |
| US-20100197609-A1 | ALKYLAMINO-SUBSTITUTED DICYANOPYRIDINES AND THEIR AMINO ACID ESTER PRODRUGS | DNPEP, DDC, AADAC | ADORA1 755/4885SLC6A3 687/4885 |
| US-20160311812-A1 | ADENOSINE A1 AGONISTS AS MEDICAMENTS FOR KIDNEY DISORDERS | ADORA1, ADORA2A, ADORA2B | ADORA1 1/4885SLC6A3 1206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.